MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation
Lingtao Jin(Emory University), Sumin Kang(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Guojing Zhang(Emory University), Lawrence Boise(Emory University), Jeanne Kowalski(The University of Texas at Austin), Lu Zhou(Fudan University), Sagar Lonial(Emory University), Titus J. Boggon(Yale Cancer Center), Georgia Z. Chen(Emory University), Nabil F. Saba(Emory University), Chaoyun Pan(Emory University), Gina N. Alesi(Emory University), Fadlo R. Khuri(American University of Beirut Medical Center), Hee‐Bum Kang(Emory University), Kelly R. Magliocca(Emory University), Jaemoo Chun(Korea Institute of Oriental Medicine), Cheng‐Kui Qu(Emory University), Dan Li(Brigham Young University), Xu Wang(Western University), Dongsheng Wang(University of California San Diego), Jun Fan(Icahn School of Medicine at Mount Sinai), Lina Song(Hubei University of Medicine), Ruiting Lin(Guangzhou University of Chinese Medicine), Conor E. Steuer(Emory University), Dong M. Shin(Emory University)
Cited by 155
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k